Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Breast 1

Conditions

Stomach Neoplasms 2Pancreatic Neoplasms 1Esophageal Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Colorectal Neoplasms 1Breast Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Cisplatin 3193Cyclophosphamide 3187Carboplatin 2968Radiotherapy 2784Paclitaxel 2716Gemcitabine 2569pembrolizumab 2378Bevacizumab 2206Docetaxel 2196Fluorouracil 1848Capecitabine 1828Oxaliplatin 1738Dexamethasone 1604Nivolumab 1580Doxorubicin 1501Rituximab 1487Magnetic Resonance Spectroscopy 1382Etoposide 1345Irinotecan 1245Leucovorin 1222Drug Therapy 1202Cytarabine 1130Pemetrexed 1074fludarabine 1056Specimen Handling 1009Vincristine 964Cetuximab 943Prednisone 940Trastuzumab 940Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
uridine triacetate × Clear all
NCT00024427 2012-06-28

Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer

Wellstat Therapeutics

Phase 3 Completed
250 enrolled
Gastrointestinal

Pancreatic Neoplasms, Drug-Related Side Effects and Adverse Reactions

NCT00004233 2011-07-25

S9915 Triacetyluridine, Fluorouracil, and Leucovorin in Treating Patients With Unresectable, Locally Advanced, or Metastatic Cancer of the Esophagus or Stomach

SWOG Cancer Research Network

Phase 2 Completed
65 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Stomach Neoplasms

NCT00044785 2005-06-24

Phase I Study of PN401, Fluorouracil, Leucovorin and CPT-11 in Patients With Solid Tumors

Wellstat Therapeutics

Phase 1 Terminated
24 enrolled
BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡